Abera Bioscience AB (FRA:8WK)

Market Cap	11.49M +111.1%
Revenue (ttm)	1.56M +37.2%
Net Income	-131.52K
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5150
Previous Close	0.5350
Day's Range	0.5000 - 0.5650
52-Week Range	0.3020 - 0.8350
Beta	n/a
RSI	52.98
Earnings Date	Feb 12, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 5
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8WK

Financial Performance

In 2024, Abera Bioscience AB's revenue was 14.63 million, an increase of 479.60% compared to the previous year's 2.52 million. Losses were -1.10 million, -93.42% less than in 2023.

Financial numbers in SEK